OBJECTIVES: The aim of this study was conducted to estimate the cost-effectiveness of cetuximab combined with radiotherapy compared to radiotherapy alone in patients with locally advanced squamous cell carcinoma of head and neck. METHODS: A decision-tree analysis was used to compare cetuximab combined with radiotherapy and radiotherapy alone in the treatment of patients with locally advanced squamous cell carcinoma of head and neck from the perspective of the Bureau of National Health Insurance(BNHI) in Taiwan. The model was based on individual patient data extracted from an international phase III trial. The direct medical costs of care were based on the reimbursement of Bureau of National Health Insurance in Taiwan. One-way sensitivity analyses were performed with varying the costs and clinical parameters. RESULTS: The incremental cost per quality-adjusted life-year for patients receiving radiotherapy in combination with cetuximab compared to radiotherapy alone was in the range of $70,469/yr to $542,334/yr in the base-case analysis. Sensitivity analysis showed the robust results. CONCLUSIONS: This study demonstrated the addition of cetuximab to high-dose radiotherapy regimen is likely to be cost-effective in consideration of higher locoregional control rate to be achieved compared to radiotherapy alone for locally advanced head and neck cancer in Taiwan.
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HTA Consulting, Krakow, Poland, 2 Sanofi-Aventis Sp. z o.o., Warsaw, Poland OBJECTIVES: The aim of present analysis was to assess cost-effectiveness of lenograstim in comparison with other G-CSFs-filgrastim and pegfilgrastim in Polish settings (threshold is about 100,095 PLN). METHODS: Analysis covered time horizon of one chemotherapy cycle. A public payer perspective was adopted for cost analysis. The costs included were based on Polish NHF reference costs list. Data on time to ANC recovery, number of days with fever, length of hospital stay and antibiotics use were obtained from randomized controlled trials (RCTs) identified in the conducted systematic review. These included trials on prophylactic G-CSF use as well as trials in which only patients with neutropenia were included. Equations describing costs and QALY according to neutropenia and fever length, hospital stay and antibiotic use were established. RESULTS: Estimated QALY difference between lenograstim and filgrastim is 0.0041 (CI95%[0.0007; 0.0079]), compared to pegfilgrastim is 0.0039 (CI95%[0.0004; 0.0077]). Total costs difference between lenograstim and filgrastim is −2,069 PLN (CI95% [−5,385; −1,039] ) and compared to pegfilgrastim is 266 PLN (CI95% [−3,233; 3,633] ). The ICER in comparison with pegfilgrastim is 68,424 PLN. Probability of lenograstim being cost-effective over filgrastim is 91.54% and over pegfilgrastim is 51.41%. Taking into account only trials where G-CSFs were used in neutropenia prophylaxis estimated QALY difference between lenograstim and filgrastim is 0.0049 (CI95%[0.0013; 0.0088]), compared to pegfilgrastim is 0.0047 (CI95%[0.0011; 0.0086]). Total costs difference between lenograstim and filgrastim is −2,724 PLN (CI95% [−6,139; −475] ) and compared to pegfilgrastim is −434 PLN (CI95%[−4,025; 2,996]). Probability of lenograstim being cost-effective over filgrastim is 96.12% and over pegfilgrastim is 66.82%. CONCLUSIONS: Lenograstim is dominant over filgrastim and cost-effective in comparison with pegfilgrastim. Acknowledgements: This analysis was supported by Sanofi-Aventis.
PCN89 COST EFFECTIVENESS ANALYSIS OF A CLINICAL PATHWAY FOR THE SURVEILLANCE OF HEPATOCARCINOMA IN COLOMBIA
Romero M, Arango C, Albanes J Fundacion Salutia, bogota, Colombia OBJECTIVES: The objetive of this paper is an analysis of cost effectiveness of a proposed clinical pathway for the surveillance of hepatocellular carcinoma in Colombia compared to conventional management METHODS: Economic evaluation is performed by designing a Markov model to simulate two cohorts, one under a surveillance program through the combined use of alpha-fetoprotein and ultrasound every 6 months and another with the current monitoring scheme with a time horizon of 30 years and age of onset of 30 years, a rate adjustment of 3% the initial cohort of 100 patients RESULTS: The cost in the surveillance group is US $ 1,495.548 and unguarded arm is U.S. $ 798,714. With the surveillance program presents 21 deaths caused by the disease compared with 35 deaths without monitoring program, with 688 years of life gained and an ICER of US$ 670. As demonstrated in other studies, the performing monitoring for HCC reduces mortality in the population at risk. The clinical pathway implementation of surveillance for HCC in people with liver cirrhosis and HBV and HCV infection is very cost effective compared with doing nothing from the perspective of third-party payer in Colombia. The results maintain the costeffectiveness in the sensitivity analysis without major changes. CONCLUSIONS: The implementation of a monitoring method with alpha-fetoprotein and ultrasound every two years is cost effective. We recommend the implementation of clinical pathway assessed for its cost effectiveness in the light of life years gained as outcome. MPT. The analytic framework is based on 'partitioned survival analysis' that allows survival data to be decomposed into three states: 1) alive before disease progression; 2) alive after progression; and 3) dead. The model estimates mean OS, qualityadjusted life-years (QALYs), costs and cost per QALY over a 30-year time horizon, and performs both 1-way and probabilistic sensitivity analyses. RESULTS: VMP's mean OS is 61 months compared to 42.7 and 50.2 months for MP and MPT, respectively. Mean lifetime direct medical costs per patient are approximately SEK 1,193,000, 604,000 and 920,000 for VMP, MP and MPT, respectively. Mean incremental cost per QALY of VMP compared to MP is SEK 676, 415; 90 percent C.I. (335, 578, 710, 135) and SEK 576, 823; 90 percent C.I. (0, 1, 444, 278) compared to MPT. The two most influential variables in our model are 1) VMP to MP hazard ratio; and 2) utility after progression. CONCLUSIONS: VMP and MPT are projected to prolong survival relative to MP. Having ICERs less than SEK 700,000, we believe that from a Swedish perspective, VMP is cost-effective compared to both MP and MPT. 
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